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Abstract 
Background: Mortality due to COVID‑19 is high, especially in patients requiring mechanical ventilation. The purpose 
of the study is to investigate associations between mortality and variables measured during the first three days of 
mechanical ventilation in patients with COVID‑19 intubated at ICU admission.
Methods: Multicenter, observational, cohort study includes consecutive patients with COVID‑19 admitted to 44 
Spanish ICUs between February 25 and July 31, 2020, who required intubation at ICU admission and mechanical ven‑
tilation for more than three days. We collected demographic and clinical data prior to admission; information about 
clinical evolution at days 1 and 3 of mechanical ventilation; and outcomes.
Results: Of the 2,095 patients with COVID‑19 admitted to the ICU, 1,118 (53.3%) were intubated at day 1 and 
remained under mechanical ventilation at day three. From days 1 to 3,  PaO2/FiO2 increased from 115.6 [80.0–171.2] to 
180.0 [135.4–227.9] mmHg and the ventilatory ratio from 1.73 [1.33–2.25] to 1.96 [1.61–2.40]. In‑hospital mortality was 
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Background
The mortality recorded during the COVID-19 pandemic, 
although variable, is extremely high, especially in patients 
admitted to the ICU, and even more in those patients 
that require invasive mechanical ventilation (MV) for 
ARDS [1]. In a recent meta-analysis including 69 stud-
ies, the overall case fatality rate was 45% [2]. When cases 
were stratified by age, mortality rise to 84.4% in patients 
older than 80 years. However, the observed heterogene-
ity was high (I > 90%) but with a non-significant Egger 
regression test that suggested no publication bias. The 15 
studies included from Europe gave similar results com-
pared to other continents [2].
The Eurosurveillance registry in Spain [3] reported epi-
demiological data from the first wave of the pandemic in 
Spain up to April 17, 2020. They reported 8,289 patients 
admitted to ICUs (4.6% of the total), 4,085 of whom 
required MV (78% of those admitted to an ICU). The 
overall mortality of mechanically ventilated patients was 
42%. Among the various factors associated with death, 
age, chronic kidney disease, and a shorter time between 
symptom onset and ED visit were the most important. 
The REVA network study [4] recently described 4,643 
patients admitted to ICUs in France. On day 1 of admis-
sion, 63% of patients were intubated and overall, 80% 
received MV. The 90-day mortality was associated with 
age, diabetes, obesity, and severe ARDS.
The majority of investigations dealing with COVID 
patients admitted to the ICU have attempted to deter-
mine prognostic factors using data from the first day 
of hospital admission or data obtained on day 1 of ICU 
admission. In ICU patients, these data can be misinter-
preted, either because the patients are not “clinically sta-
ble” or because they are not relevant as they cannot be 
modified (e.g., age, obesity, etc.). On the other hand, in 
many respiratory acute diseases with acute respiratory 
failure, the patient’s status 72 h after ICU admission gives 
important clues about prognosis, taking into account 
what has happened since admission, including adequate 
or inadequate management [5, 6]. This type of observa-
tional research can provide evidence about beneficial 
medical interventions.
CIBERESUCICOVID (Centro de Investigación Biomé-
dica En Red de Enfermedades ReSpiratoria—Factores de 
riesgo y pronóstico personalizados y seguimiento a un 
año de los enfermos ingresados en las Unidades de Cui-
dados Intensivos españolas infectados por COVID-19) is 
a multicenter observational study (NCT04457505) that is 
studying patients admitted to an ICU due to SARS-CoV-2 
infection [7]. Patients who required invasive mechanical 
ventilation during the first day of admission to the ICU 
and who remained ventilated 3 days later were selected to 
capture what has happened since admission to 72 h after 
ICU admission. Our hypothesis was that the differences 
between day 1 and day 3 in relevant and independently 
associated variables with in-hospital mortality may help 
clinicians both to establish corrective measures and to 
have a better understanding of the prognosis.
Methods
Study design
CIBERESUCICOVID is a multicenter, observational, pro-
spective/retrospective cohort study that enrolled patients 
with COVID-19 infection admitted to the Spanish 
ICUs (participating centers are listed in the Additional 
file  1: Table  1). The study was approved by the Institu-
tion’s Internal Review Board (Comité Ètic d’Investigació 
Clínica, registry number HCB/2020/0370), and informed 
consent was obtained from either patients or their rela-
tives. Local researchers were contacted by a member of 
the study team and participating hospitals obtained local 
ethics committee approval. Data collection was started 
in May 2020. Consecutive patients admitted before the 
start of the study were included retrospectively. Patients 
admitted after the start of the study were included pro-
spectively. De-identified patient data were collected 
and stored via the REDCap electronic data capture tool, 
hosted at the Centro de Investigación Biomédica en Red 
(CIBER), Spain. Data from patients’ medical records were 
incorporated into a separate database by trained local 
researchers. Prior to statistical analyses, the data were 
checked by three independent experienced data collec-
tors trained in critical care (PC, AM, CS), and site investi-
gators were contacted with any queries. Missing analyses 
were performed, and site investigators were contacted 
38.7%. A higher increase between ICU admission and day 3 in the ventilatory ratio (OR 1.04 [CI 1.01–1.07], p = 0.030) 
and creatinine levels (OR 1.05 [CI 1.01–1.09], p = 0.005) and a lower increase in platelet counts (OR 0.96 [CI 0.93–1.00], 
p = 0.037) were independently associated with a higher risk of death. No association between mortality and the  PaO2/
FiO2 variation was observed (OR 0.99 [CI 0.95 to 1.02], p = 0.47).
Conclusions: Higher ventilatory ratio and its increase at day 3 is associated with mortality in patients with COVID‑19 
receiving mechanical ventilation at ICU admission. No association was found in the  PaO2/FiO2 variation.
Keywords: Ventilatory ratio, Mechanical ventilation, COVID‑19, SARS‑CoV‑2, Coronavirus
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Table 1 Demographic and clinical characteristics of patients that received invasive mechanical ventilation (MV) during the first 24 h of 
ICU admission
No All patients (n = 1118) Survivors (n = 685) Non-survivors (n = 433) p-value
Age, years 1118 65.0 [57.0–72.0] 62.0 [53.0–69.0] 69.0 [63.0–74.0]  < 0.001
Age, categories 1118
 < 50 144 (12.9%) 125 (18.3%) 19 (4.4%)  < 0.001
 50–69 612 (54.7%) 407 (59.4%) 205 (47.3%)  < 0.001
 70–79 345 (31.0%) 149 (21.8%) 197 (45.5%)  < 0.001
  ≥ 80 16 (1.4%) 4 (0.6%) 12 (2.8%) 0.004
Sex, female 1118 322 (28.8%) 211 (30.8%) 111 (25.6%) 0.07
BMI, kg/m2 1019 28.1 [25.6–31.5] 28.3 [25.7–31.6] 27.8 [25.5–31.3] 0.27
Comorbidities
 Active smoker 741 61 (8.2%) 33 (7.1%) 28 (10.4%) 0.17
 Hypertension 1117 555 (49.7%) 308 (45.0%) 247 (57.2%)  < 0.001
 Diabetes mellitus 1117 258 (23.1%) 153 (22.3%) 105 (24.3%) 0.47
 Dyslipidemia 1117 275 (24.6%) 165 (24.1%) 110 (25.4%) 0.62
 Chronic cardiac failure 1117 138 (12.4%) 60 (8.8%) 78 (18.1%)  < 0.001
 Chronic kidney disease 1117 58 (5.1%) 25 (3.6%) 33 (7.4%) 0.003
 Chronic respiratory disease 1117 119 (10.7%) 52 (7.6%) 67 (15.5%)  < 0.001
Days since first symptoms 1098 7.0 [5.0–9.0] 7.0 [5.0–9.0] 7.0 [4.0–9.0] 0.047
Days from hospital admission to intubation 1116 1.0 [0.0–4.0] 1.0 [0.0–3.0] 1.0 [0.0–4.0] 0.38
APACHE score 615 12.0 [9.5–16.0] 11.0 [8.8–15.0] 14.0 [11.0–18.0]  < 0.001
SOFA score 779 7.0 [5.0–8.0] 7.0 [4.0–8.0] 7.0 [5.0–9.0]  < 0.001
SOFA hemodynamic component 1041 3.0 [0.0–4.0] 3.0 [0.0–4.0] 3.0 [0.0–4.0] 0.09
SOFA renal component 1108 0.0 [0.0–0.0] 0.0 [0.0–0.0] 0.0 [0.0–1.0]  < 0.001
Temperature, ºC 995 36.9 [36.0–37.8] 37.0 [36.0–37.9] 36.8 [36.0–37.8] 0.08
Respiratory rate, bpm 942 25.0 [20.0–30.0] 24.0 [20.0–30.0] 25.0 [20.0–30.0] 0.63
Arterial blood gases at ICU admission
  PaO2/FiO2 ratio, mmHg 1067 115.6 [80.0–171.2] 117.5 [82.2–176.7] 111.27 [74.1–157.9] 0.017
  PaO2/FIO2 ratio categories 1067
  PaO2/FiO2 ratio < 100 mmHg 424 (39.7%) 249 (37.4%) 175 (43.5%) 0.05
  PaO2/FiO2 ratio ≥ 100 and < 200 mmHg 462 (43.3%) 295 (44.4%) 167 (41.5%) 0.37
  PaO2/FiO2 ratio ≥ 200 and < 300 mmHg 132 (12.4%) 88 (13.2%) 44 (11.0%) 0.29
  PaO2/FiO2 ratio ≥ 300 mmHg 49 (4.6%) 33 (5.0%) 16 (4.0%) 0.55
 pH 1076 7.36 [7.29–7.43] 7.38 [7.31–7.44] 7.33 [7.26–7.41]  < 0.001
  PaCO2, mmHg 1084 43.9 [36.0–52.0] 43.0 [36.0–50.5] 45.1 [37.0–55.0] 0.001
 Lactate, mg/dL 753 13.0 [9.9–17.1] 12.6 [9.0–16.2] 14.4 [10.8–18.9]  < 0.001
Laboratory findings at ICU admission
 Lymphocyte count,  109/L 1095 0.63 [0.43–0.90] 0.67 [0.47–0.95] 0.60 [0.40–0.84] 0.001
 Neutrophil count,  109/L 472 7.66 [5.57–11.32] 7.32 [5.30–10.84] 7.97 [5.81–12.00] 0.10
 Platelet count,  109/L 1106 226.0 [173.0–299.0] 236.0 [182.0–308.8] 212.0 [163.8–277.3]  < 0.001
 D‑dimers, mg/L 877 1.12 [0.59–3.52] 0.98 [0.53–2.30] 1.71 [0.70–5.51]  < 0.001
 Ferritin, ng/mL 379 1398 [821–2250] 1330 [766–2172] 1500 [890–2400] 0.11
 IL6, pg/mL 215 114.0 [47.5–181.4] 103.1 [45.1–186.8] 125.9 [60.2–153.2] 0.66
 CRP, mg/dL 987 17.5 [9.4–26.6] 17.0 [9.1–26.0] 18.4 [10.0–27.7] 0.068
 Bilirubin, mg/dL 1018 0.62 [0.42–1.00] 0.64 [0.43–1.00] 0.60 [0.40–1.00] 0.76
 Serum creatinine, mg/dL 1108 0.87 [0.67–1.15] 0.82 [0.64–1.07] 0.95 [0.75–1.28]  < 0.001
Ventilatory setting and pulmonary mechanics at MV start
 Tidal volume/PBW (mL/kg) 908 7.1 [6.4–8.0] 7.1 [6.4–7.9] 7.1 [6.4–8.0] 0.80
 Respiratory rate, bpm 999 20.0 [18.0–24.0] 20.0 [18.0–24.0] 20.0 [18.0–24.0] 0.63
 PEEP,  cmH2O 1045 12.0 [10.0–14.0] 12.0 [10.0–14.0] 12.0 [10.0–14.0] 0.52
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in order to obtain reliable and complete data as much as 
possible (Additional file 1: Fig. 1). Results were reported 
in accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) guide-
lines [8].
Study population and data collection
All consecutive patients admitted to the ICU at a par-
ticipating center from February 25 to July 31, 2020, were 
enrolled if they fulfilled the following criteria: ≥ 18 years 
old, admission to ICU, and laboratory confirmed SARS-
CoV-2 infection. For this study, we selected those patients 
who required invasive mechanical ventilation during the 
first day of admission to the ICU and who remained ven-
tilated 3  days later. This selection responded to capture 
what has happened during first days of ICU admission 
in a homogenous population. Patients were excluded if 
they had non-confirmed SARS-CoV-2 infection, no data 
at baseline or at hospital discharge, or who were admit-
ted to an ICU for other reasons. Patients who required 
ECMO support within this period (i.e., ICU admission—
Day 3) were excluded from the analysis to avoid potential 
bias in blood gases analysis and pulmonary mechanics 
[9].
After enrollment, prior epidemiological data includ-
ing demographics, comorbidities, clinical symptoms, 
disease chronology, and treatment administered upon 
hospital admission were collected. The site research-
ers subsequently collected data acquired at hospital 
admission, ICU admission, start of MV, 72–96  h after 
ICU admission, weaning, ICU discharge and hospi-
tal discharge, including vital signs, respiratory support 
devices (i.e., oxygen mask, high flow nasal cannular, and 
noninvasive and invasive mechanical ventilation), the use 
of adjunctive therapies (i.e., neuromuscular blockade, 
prone position, and recruitment maneuvers), laboratory 
findings, arterial blood gases, and mechanical ventila-
tion settings if appropriate. Hemodynamic parameters 
and organ dysfunction were studied with the Sequential 
Organ Assessment Failure Score (SOFA) at ICU admis-
sion. The pharmacological treatments administered upon 
and during ICU admission until either discharge from 
the ICU or hospital, or death, were also collected.
Specific data regarding MV since the start of intuba-
tion, as well as, at day 3 were analyzed. MV parameters 
related to ventilation-induced lung injury (VILI) such as 
tidal volume, respiratory rate, end-inspiratory plateau 
and peak inspiratory pressures, positive end-expiratory 
pressure (PEEP), driving pressure, and static compliance 
of the respiratory system (Crs) were collected. Impair-
ment in oxygenation was analyzed using the  PaO2/FiO2 
ratio and abnormalities of  CO2 metabolism were stud-
ied using the ventilatory ratio (VR), a surrogate param-
eter of Vd/Vt. The worst event values were preferentially 
recorded.
Definitions
The diagnosis of ARDS was based on the Berlin defini-
tion [10]. Chronic respiratory disease was defined as any 
chronic obstructive pulmonary disease, cystic fibrosis, 
bronchiectasis, and interstitial lung diseases, exclud-
ing asthma [11]. Tidal volume was reported in mL/kg 
of predicted body weight (PBW). Driving pressure was 
defined as plateau pressure minus PEEP. Crs was calcu-
lated as tidal volume/ (plateau pressure − PEEP). Ventila-
tory ratio was defined as (minute ventilation x  PaCO2)/
Table 1 (continued)
No All patients (n = 1118) Survivors (n = 685) Non-survivors (n = 433) p-value
  FiO2, % 1064 75.0 [60.0–100.0] 70.0 [60.0–100.0] 80.0 [60.0–100.0]  < 0.001
 Peak inspiratory pressure,  cmH2O 509 31.0 [27.0–35.0] 30.0 [27.0–34.0] 31.0 [27.5–35.5] 0.08
 End‑inspiratory plateau pressure,  cmH2O 440 25.0 [22.0–28.0] 25.0 [21.0–28.0] 25.0 [22.0–28.0] 0.10
 Driving pressure,  cmH2O
a 432 12.0 [9.6–15.0] 12.0 [9.0–14.0] 12.0 [9.8–15.0] 0.25
 Compliance, mL/cmH2O
b 413 37.1 [29.3–50.0] 37.1 [30.0–50.0] 35.8 [28.2–50.0] 0.33
 Ventilatory  ratioc 889 1.73 [1.33–2.25] 1.68 [1.32–2.15] 1.87 [1.41–2.36] 0.001
 Position 960
 Supine 591 (61.6%) 394 (65.5%) 197 (55.0%)  < 0.001
 Prone 346 (36.0%) 192 (31.9%) 154 (43.0%) 0.008
 Other 23 (2.4%) 16 (2.6%) 7 (2.0%) 0.46
Continuous variables are expressed as median (IQR) and categorical variables as number (percentages). P-values marked in bold indicate numbers that are significant 
on the 95% confidence limit. CRP C-reactive protein; FiO2 fraction of inspired oxygen; MV mechanical ventilation; PaCO2 arterial partial pressure of carbon dioxide; 
PaO2 partial pressure of arterial oxygen; PBW predicted body weight; SOFA sequential organ failure assessment score
a Defined as plateau pressure—PEEP
b Defined as tidal volume/(Plateau pressure − PEEP)
c Defined as (minute ventilation ×  PaCO2)/(PBW × 100 × 37.5)
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Fig. 1 Flowchart of patient screening and enrollment. A total of 1118 patients were followed‑up until hospital discharge or death. ECMO 
extracorporeal membrane oxygenation; ICU intensive care unit; SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
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(PBW × 100 × 37.5) (normal value: 1). The delta meas-
urements were computed as the difference between the 
value at day 3 of ICU admission and day 1 of ICU admis-
sion. Other definitions were reported in the Online Sup-
plementary Data.
Outcomes
The primary outcome was in-hospital mortality. ICU 
mortality, 28  days mortality, the duration of ventilation, 
ICU, and hospital length of stay were also collected and 
reported. The pulmonary (i.e., nosocomial pneumonia, 
tracheobronchitis, ARDS, pneumothorax, pleural effu-
sion, pulmonary embolism) and extrapulmonary compli-
cations (including complications that affect hematologic, 
cardiovascular, renal, gastrointestinal, hepatic, endocrin-
ologic, and neurologic systems) during ICU admission 
were also collected and included at hospital discharge.
Statistical analysis
We report the number and percentage of patients for cat-
egorical variables and the median [first quartile − third 
quartile] for continuous variables. Percentages were cal-
culated excluding missing data. Categorical variables 
were compared using the Chi-squared test or Fisher’s 
exact test, whereas continuous variables were compared 
using the nonparametric Mann–Whitney U test.
To explore the risk factors associated with in-hospital 
death, mixed-effects multivariable models [12, 13] were 
used, defined by a binomial probability distribution and 
a logit link function, with centers as a random effect. 
The following variables were included in the first mul-
tivariable model based on clinical relevance only: age, 
sex, hypertension, chronic respiratory disease, SOFA 
hemodynamic component, and at ICU admission:  PaO2/
FiO2 ratio, serum creatinine, lymphocyte count, plate-
let count, D-dimer, total bilirubin, and ventilatory ratio. 
The following variables were included in the second 
multivariable model based on previous findings and 
clinical constraints: age, delta  PaO2/FiO2 ratio, delta 
serum creatinine, delta lymphocyte count, delta platelet 
count, delta total bilirubin, and delta ventilatory ratio. 
Both models included the relevant ventilatory and oxy-
genation variables, laboratory tests, organ support, and 
demographic characteristics. Odds ratios (ORs) and their 
95% confidence intervals were calculated. Single collin-
earity was evaluated using the Pearson’s coefficient cor-
relation (r). SOFA was excluded because of collinearity 
(r >|± 0.30|) with creatinine, while  PaCO2 and pH were 
omitted because ventilatory ratio collinearity. Multicol-
linearity was examined by means of the variance infla-
tion factor (VIF). A rule of thumb is that if VIF > 10, 
then multicollinearity is high [14]. The linearity of con-
tinuous variables was assessed using the Box–Tidwell test 
(Additional file 1: Table 2). The linearity assumption for 
delta measurements was confirmed in a scatter plot of the 
predictor against the logit because the Box–Tidwell test 
does not accept negative values (Additional file 1: Fig. 2). 
Variables not satisfying this criterion were entered as 
restricted cubic splines in the model. The receiver operat-
ing characteristic curve was used to assess the discrimi-
natory ability of the model to distinguish dead patients 
from living patients and is expressed as the area under 
the receiver operating characteristic curve (AUC), rang-
ing from 0.5 (no discriminative ability) to 1.0 (perfect 
discriminative ability). Calibration was assessed using the 
Brier score, ranging from 0.0 to 1.0, where a model with 
perfect skill has a score of 0.0 and the worst has a score of 
1.0. The level of significance was set at 0.05 (two-tailed), 
and all analyses were performed using R version 4.0.3.
Results
Demographics and clinical characteristics at ICU admission
Between February 25 and July 31, 2020, 2,095 patients 
with COVID-19 were admitted to 44 ICUs (Additional 
file  1: Table  3), 1,645 (78.5%) required MV (Additional 
file  1: Table  4), and 1,188 (72.2%) needed intubation on 
the first day of ICU admission (Fig.  1). The majority of 
this last cohort still received MV support at day three 
of ICU admission [1,118 (94.1%)], while 38 (3.1%) died 
and 22 (1.8%) could be extubated during these first three 
days. Ten patients (0.8%) who required ECMO support 
during these first three days were excluded.
The characteristics of the study population of patients 
needing intubation on the first day and still needing MV 
of the third day are detailed in Table 1. In summary, the 
mean age was 65.0 [57.0–72.0] years, with the majority 
(54.7%) being aged between 50 and 69 years. Seventy-one 
percent (n = 786) were male, the most frequent comorbid-
ity was hypertension, which was present in 555 (49.7%), 
and only 61 (8.2%) were active smokers. On the first day 
of MV, patients showed a respiratory system compliance 
of 37.1 [29.3–50.0] mL/cmH2O, with a driving pressure 
of 12.0 [9.6–15.0]  cmH2O, a tidal volume of 7.1 [6.4–8.0] 
mL/Kg and a ventilatory ratio of 1.7 [1.4–2.3]. The  PaO2/
FiO2 ratio was 115.6 [80.0–171.2] mmHg, and the ratio 
was under 200 mmHg in 886 (83.0%) patients and under 
100  mmHg in 424 (39.7%); 346 (36.0%) patients needed 
prone positioning during this first MV day. The measured 
respiratory rate was 20.0 [18.0–24.0] bpm, with a  PaCO2 
of 43.9 [36.0–52.0] mmHg and a pH of 7.36 [7.29–7.43]. 
The level of lactate was 13.0 [9.9–17.1] mg/dL with 704 
(67.6%) patients needing vasoactive drugs at this time 
point. The SOFA score was 7.0 [5.0–8.0], the median level 
of creatinine was 0.87 [0.67–1.15] mg/dL, and the plate-
let count was 226.0 [173.0–299.0] ×  109/L. Regarding the 
COVID-19 laboratory biomarkers, the mean lymphocyte 
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count was low (0.63 [0.43–0.90] ×  109/L) and the plasma 
levels of D-dimer, ferritin, and IL-6 were notably elevated 
with median values of 1.12 [0.59–3.52] mg/L, 1389.0 
[821.0–2250.0] ng/mL and 114.0 [47.5–181.4] pg/mL, 
respectively.
Clinical evolution at day 3 of ICU admission
The main findings at the third MV day are displayed in 
Table 2. Delta differences between day 3 and ICU admis-
sion showed a general increase in the  PaO2/FiO2 ratio 
(+ 46.7 [–9.3 to 108.3]), but this increment was not sig-
nificantly higher in patients that survived to hospital 
discharge (p = 0.07). On the contrary, we found differ-
ences in the changes in the level of  PaCO2 (+ 2.3 [–5.4 
to + 10.0] vs. + 4.3 [–5.0 to + 13.1] mmHg, p = 0.007) 
Table 2 Laboratory findings and ventilation management of the early ventilated patients at day 3 according to in‑hospital mortality
Continuous variables are expressed as median (IQR) and categorical variables as number (percentages). P-values marked in bold indicate numbers that are significant 
on the 95% confidence limit. CRP C-reactive protein; FiO2 fraction of inspired oxygen; PaCO2 arterial partial pressure of carbon dioxide; PaO2 partial pressure of arterial 
oxygen; PBW predicted body weight
a Defined as plateau pressure—PEEP
b Defined as tidal volume/(Plateau pressure − PEEP)
c Defined as (minute ventilation ×  PaCO2) / (PBW × 100 × 37.5)
No All patients (n = 1118) Survivors (n = 685) Non-survivors (n = 433) p-value
Arterial blood gases
  PaO2/FiO2 ratio, mmHg 1054 180.0 [135.4–227.9] 190.0 [148.6–237.5] 158.0 [114.0–208.7]  < 0.001
  PaO2/FiO2 ratio categories 1054
  PaO2/FiO2 ratio < 100 mmHg 98 (9.3%) 36 (5.6%) 63 (15.2%)  < 0.001
  PaO2/FiO2 ratio ≥ 100 and < 200 mmHg 550 (52.2%) 317 (49.4%) 233 (56.6%) 0.023
  PaO2/FiO2 ratio ≥ 200 and < 300 mmHg 313 (29.7%) 232 (36.1%) 81(19.7%)  < 0.001
  PaO2/FiO2 ratio ≥ 300 mmHg 91 (8.6%) 56 (8.7%) 35 (8.5%) 1.00
 pH 1082 7.39 [7.33–7.44] 7.40 [7.35–7.45] 7.37 [7.30–7.41]  < 0.001
  PaCO2, mmHg 1090 47.0 [41.8–54.0] 46.0 [40.0–51.0] 50.3 [44.0–58.0]  < 0.001
 Lactate, mg/dL 756 15.3 [11.7–20.1] 15.3 [11.1–19.8] 16.6 [12.6–20.7] 0.001
Laboratory findings
 Lymphocyte count,  109/L 1090 0.64 [0.41–1.00] 0.70 [0.48–1.00] 0.60 [0.38–0.90]  < 0.001
 Neutrophil count,  109/L 472 7.58 [5.60–10.50] 7.40 [5.24–10.29] 8.10 [6.10–10.5] 0.030
 Platelet count,  109/L 1095 255.0 [189.0–325.0] 274.0 [206.5–340.0] 222.5 [168.8–293.0]  < 0.001
 D‑dimers, mg/L 754 2.31 [1.05–6.52] 1.97 [0.96–4.76] 3.27 [1.39–8.92]  < 0.001
 Ferritin, ng/mL 345 1326 [835–2200] 1308 [790–2144] 1361 [839–2244] 0.50
 IL6, pg/mL 115 98.0 [43.1–196.6] 81.0 [44.4–191.0] 125.9 [41.7–196.9] 0.51
 CRP, mg/dL 925 10.0 [3.4–22.6] 9.3 [3.1–20.7] 10.8 [3.8–23.5] 0.09
 Bilirubin, mg/dL 957 0.75 [0.42–1.30] 0.75 [0.42–1.26] 0.76 [0.42–1.35] 0.71
 Serum creatinine, mg/dL 1101 0.92 [0.67–1.39] 0.81 [0.62–1.17] 1.10 [0.78–1.88]  < 0.001
Ventilatory setting and pulmonary mechanics
 Tidal volume/PBW (ml/kg) 926 7.3 [6.5–8.1] 7.3 [6.5–8.1] 7.3 [6.5–8.1] 0.81
 Respiratory rate, rpm 1006 22.0 [18.0–24.0] 21.0 [18.0–24.0] 22.0 [20.0–25.0] 0.003
 PEEP,  cmH2O 1051 12.0 [10.0–14.0] 12.0 [10.0–14.0] 12.0 [10.0–14.0] 0.46
  FiO2, % 1065 50.0 [40.0–60.0] 50.0 [40.0–60.0] 60.0 [50.0–70.0]  < 0.001
 Peak inspiratory pressure,  cmH2O 537 30.0 [27.0–35.0] 30.0 [27.8–34.6] 33.0 [27.0–36.0] 0.11
 End‑inspiratory plateau pressure,  cmH2O 413 24.0 [21.0–28.0] 24.0 [21.0–27.0] 25.0 [22.0–29.0] 0.001
 Driving pressure,  cmH2O
a 401 12.0 [10.0–15.0] 12.0 [9.5–14.0] 12.2 [10.0–16.0] 0.022
 Compliance, mL/cmH2O
b 399 37.5 [28.8–48.0] 38.4 [30.0–48.3] 34.6 [25.1–46.6] 0.032
 Ventilatory  ratioc 905 1.96 [1.61–2.40] 1.86 [1.53–2.24] 2.11 [1.77–2.68]  < 0.001
 Position 967
 Supine 658 (68.0%) 451 (74.0%) 219 (58.6%)  < 0.001
 Prone 285 (29.5%) 138 (23.3%) 145 (38.8%)  < 0.001
 Other 24(2.5%) 16 (2.7%) 9 (2.4%) 0.84
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and the magnitude of the ventilatory ratio (+ 0.14 [–0.18 
to + 0.47] vs. + 0.32 [–0.17 to + 0.75], p < 0.001) between 
survivors and non-survivors. In this regard, the delta of 
D-dimer was the only COVID-19 biomarker that dif-
fered significantly between survivors and non-survivors 
Fig. 2 Comparison between ICU admission and day 3 stratified by survival status. Horizontal lines of the boxplots show median values, while the 
upper and lower lines depict the interquartile range. Dots depict values for each patient. Delta partial pressure of oxygen in arterial blood  (PaO2) did 
not vary between survivor and non‑survivor patients (A), while partial pressure of carbon dioxide in arterial blood  (PaCO2) (B), the ventilatory ratio 
(C), platelets count (D), serum creatinine (E), and D‑dimer (F) significantly differed
Table 3 Multivariable model assessing predictors of in‑hospital 
mortality (N = 619 patients)
Mixed-effects model with centers as a random effect and considering a binomial 
distribution. AUC statistic (area under the curve) is 0.79 (95% CI 0.76 to 0.83), and 
Brier score is 0.18. P-values marked in bold indicate numbers that are significant 
on the 95% confidence limit. CI confidence interval; FiO2, fraction of inspired 
oxygen; ICU, intensive care unit; PaO2, partial pressure of arterial oxygen; SOFA, 
sequential organ failure assessment score
Variable Odds ratio (95% CI) p value
Age, years 1.01 (1.01 to 1.02)  < 0.001
Sex, male 1.04 (0.96 to 1.12) 0.34
Hypertension 1.01 (0.94 to 1.09) 0.83
Chronic respiratory disease 1.16 (1.03 to 1.29) 0.013
SOFA hemodynamic component 1.01 (0.99 to 1.03) 0.53
PaO2/FiO2 ratio at ICU admission, mmHg 1.00 (0.99 to 1.00) 0.14
Serum creatinine at ICU admission, mg/dL 1.09 (1.03 to 1.15) 0.003
Lymphocyte count at ICU admis‑
sion, ×  109/L
1.00 (0.98 to 1.03) 0.89
Platelet count at ICU admission, ×  109/L 1.00 (1.00 to 1.00) 0.12
Total bilirubin at ICU admission, mg/dL 0.97 (0.91 to 1.03) 0.27
D‑dimers at ICU admission, μg/L 1.00 (1.00 to 1.00) 0.29
Ventilatory ratio at ICU admission 1.07 (1.01 to 1.14) 0.016
Table 4 Multivariable model assessing predictors of in‑hospital 
mortality (N = 660)
Mixed-effects model with centers as a random effect and considering a binomial 
distribution. AUC statistic (area under the curve) is 0.79 (95% CI 0.76 to 0.83), and 
Brier score is 0.18. P-values marked in bold indicate numbers that are significant 
on the 95% confidence limit. CI confidence interval; FiO2 fraction of inspired 
oxygen; PaO2 partial pressure of arterial oxygen
Variable Odds ratio (95% CI) p value
Age 1.01 (1.01 to 1.02)  < 0.001
Delta  PaO2/FiO2 ratio, mmHg 1.00 (1.00 to 1.00) 0.47
Delta serum creatinine, mg/dL 1.06 (1.02 to 1.11) 0.005
Delta lymphocyte count, ×  109/L 1.01 (0.98 to 1.04) 0.40
Delta platelet count, ×  109/L 0.99 (0.98 to 1.00) 0.037
Delta total bilirubin, mg/dL 0.99 (0.97 to 1.02) 0.79
Delta ventilatory ratio 1.05 (1.01 to 1.10) 0.030
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(+ 0.40 [–0.11 to + 1.69] vs. + 0.58 [–0.36 to + 3.67] mg/L, 
p = 0.001). Regarding other extrapulmonary biomarkers 
of organ dysfunction, the delta of creatinine levels was 
higher in non-survivors (+ 0.0 [–0.14 to + 0.22] vs. + 0.12 
[–0.11 to + 0.54] mg/dL, p < 0.001), and the platelet count 
increase was higher in survivors (+ 35.0 [–20.8 to + 80.0] 
vs. + 8.5 [–35.0 to + 53.0] ×  109/L, p = 0.013). Also, we 
found the variation of bilirubin was significantly higher 
in non-survivors (+ 0.04 [–0.16 to + 0.4] vs. + 0.05 [–0.16 
to + 0.56] mg/dL, p = 0.023). All these variations are 
detailed in Fig.  2 and Additional file  1: Table  5. There 
were no correlations between ventilatory ratio and prog-
nostic biomarkers, lung mechanics or gas exchange data 
except weak, yet significant correlations were found 
between ventilatory ratio and PEEP (r = 0.11, p < 0.001), 
 PaO2/FiO2(r =  − 0.19, p < 0.001) and driving pressure 
(r = 0.15, p = 0.004) at day 3 (Additional file 1: Fig. 3 and 
Table 6).
Treatments and complications during ICU admission
Among the 1,118 patients, 986 (88.8%) patients received 
Hydroxychloroquine and 892 (80.4%) Lopinavir/Rito-
navir during their ICU admission. Dexamethasone and 
methylprednisolone were used in 233 (21.4%) and 572 
(52.4%) patients, respectively, while 499 (45.0%) were 
treated with Tocilizumab. Therapeutic anticoagulation 
with heparin was administered in 1065 (96.0%) patients. 
Those that survived to hospital discharge received this 
treatment more frequently [662 (97.1% of survivors) 
vs. 403 (94.4% of non-survivors); p = 0.04]. Coagula-
tion disorders were present in 290 (26.0%) of the popu-
lation, and hemorrhage complications were identified 
in 103 (9.2%) patients. Vasopressors were needed at any 
time of ICU admission in 1028 (92.6%) patients. Acute 
renal failure was identified in 493 (44.1%) patients, and 
157 (14.1%) patients needed renal replacement therapy. 
Neuromuscular blockers were used at some point in 950 
(85.9%) patients, and 482 (43.2%) patients needed tra-
cheostomy. Recruitment maneuvers were used in 653 
(61.8%) patients, prone positioning in 874 (79.0%), and 
in 20 (1.8%) cases extracorporeal respiratory support was 
needed. According to the Berlin definition, 76 (6.8%) had 
mild ARDS, 467 (41.8%) had moderate ARDS, and 575 
(51.4%) had severe ARDS.
Although the vast majority of the cohort received 
antibiotic treatment (1102 patients, 99.2%), bacterial 
pneumonia was diagnosed in 368 (33.1%) of ventilated 
patients and bacteremia in 446 (40.0%). Thirty-three per-
cent of patients had hepatic dysfunction. Pneumothorax 
[53(7.7%) vs 55 (12.7%), p = 0.007)] and hemorrhages 
[49(7.2%) vs 54 (12.7%), p = 0.004)] were more frequent 
in non-survivor patients. Additional file  1: Table  7 lists 
COVID-19 therapies and other treatments, and Addi-
tional file 1: Table 8 displays the major complications in 
this subpopulation of 1,118 patients.
Outcomes and predictors of in-hospital mortality
The in-hospital mortality of all the COVID-19 patients 
admitted to an ICU during the study period was 32.6%, 
and that of patients needing intubation during the first 
24 h was 40.2%.
In particular, in the cohort of patients still needing 
MV at day 3, we found an overall in-hospital mortality 
of 38.7%. Specifically on this subpopulation, ICU mor-
tality was 37.5%, while 28-day mortality was 31.9%. The 
main causes of death were multiorgan failure (n = 179; 
41.7%) and respiratory failure (n = 178; 41.5%). The dura-
tion of MV, ICU, and hospital stay was 16.0 [9.0–27.0], 
20.0 [11.0–32.0], and 30.0 [19.0–48.0] days, respectively 
(Additional file 1: Table 9).
After multivariable adjustment including variables 
at day 1 of ICU admission, older age, the presence of 
chronic respiratory disease, higher levels of creatinine, 
and a higher ventilatory ratio were significantly asso-
ciated with an increased risk for in-hospital mortality 
(Table  3). Equivalent results were obtained when died 
or extubated patients during these first three days were 
included in the analysis (Additional file 1: Table 10).
Likewise, when we included in the model the change 
in variables between day 1 and 3 of ICU admission, we 
found that a higher increase in the ventilatory ratio (OR 
1.04 [CI 1.01–1.07]) and the creatinine levels (OR 1.05 
[CI 1.01–1.09]) and a lower increase in the platelet count 
(OR 0.96 [CI 0.93–1.00]) were significantly associated 
with a higher risk of death. (Table  4). Interestingly, we 
found that neither the initial  PaO2/FiO2 ratio (0.97 [CI 
0.94 to 1.01]) nor its variation (OR 0.99 [CI 0.95 to 1.02]) 
were associated with in-hospital mortality.
Discussion
The current study focused on a very homogeneous popu-
lation of COVID-19 patients that needed intubation and 
mechanical ventilation at day 1 of ICU admission and 
continued to be mechanically ventilated at day 3. The 
in-hospital mortality of these patients in the first wave 
of the pandemic was 38.7%. We investigated the factors 
associated with mortality at day 1 and more importantly, 
any changes between day 1 and day 3. The day 1 model 
found that age, chronic respiratory disease, increased 
serum creatinine, and increased ventilatory ratio were 
independent factors associated with in-hospital mortal-
ity while the day 1 vs. day 3 model identified age, higher 
increase in serum creatinine from day 1 to day 3, lower 
increase in the number of platelets from day 1 to day 3, 
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and higher increase in ventilatory ratio from day 1 to day 
3 as predictors of mortality.
The reported percentage mortality of COVID patients 
admitted to the ICU is very heterogeneous, ranging 
from 30 to 60%, and mainly due to mixed noninvasively 
and invasively mechanically ventilated populations, 
mixed periods of the pandemic and different endpoints. 
Our multicenter study shows the in-hospital mortal-
ity of a very well-defined population that needed MV 
and remained ventilated 3 days after starting ventilation 
(38.7%).
At day 1, we found some demographic variables associ-
ated with higher mortality such as age and chronic res-
piratory diseases. These factors cannot be modified and 
simply reflect a more vulnerable population in whom 
COVID-19 has a worse evolution. Other studies con-
firm that age and chronic respiratory diseases are poor 
prognostic factors both in ventilated, mixed ventilated 
and non-ventilated patients [15, 16]. Among laboratory 
tests, only higher serum creatinine at ICU admission 
was associated with in-hospital mortality. Remarkably, 
oxygenation at day 1 of MV was not a factor associated 
with higher mortality. The most comparable study to 
our investigation is that of Botta et al., who studied 533 
mechanically ventilated Dutch COVID patients [17]. 
Like us, they found that age was associated with 28-day 
mortality, while  PaO2/FiO2 was not. In our study, the 
ventilatory ratio at day 1 was associated with in-hospital 
mortality. Botta et al. [17] did not measure this surrogate 
marker of dead space. However, they showed that higher 
tidal volume and lower compliance were associated with 
increased 28-day mortality.
In this context, determining prognostic factors is cru-
cial to detect those that are amenable to medical inter-
vention. In many acute respiratory diseases that need 
MV, day 3 of evolution is crucial. In both severe commu-
nity-acquired pneumonia [18] and ventilator-associated 
pneumonia [5], the differences between day 1 and day 3 
in key physiological parameters are reliable predictors of 
evolution and prognosis. Therefore, we performed a sec-
ond multivariable model comparing day 1 and day 3 of 
MV. Overall, we found that the deltas (difference day 3 vs. 
day 1) in platelet counts (lower increase), creatinine levels 
(higher increase) and ventilatory ratio (higher increase) 
were significantly associated with in-hospital mortality. 
Changes in oxygenation were not associated with lower 
mortality.
In particular, the changes found in serum creatinine 
levels and platelets counts reflect organ failure in severe 
COVID patients. Since COVID-19 is a systemic disease 
that can affect all organs, renal failure can occur due to 
direct kidney injury [19]. Alterations in coagulation may 
have a significant impact on the platelet count, which is 
well described in severe COVID patients [19, 20]. Out-
standingly, we found that increases in ventilatory ratio 
were associated with in-hospital mortality, while there 
was no evidence that changes in the degree of hypoxemia 
worsened the prognosis in our population of COVID-19 
pneumonia ARDS patients.
The ventilatory ratio is a recently validated index that 
is appealing because it is simple to calculate using the 
minute ventilation and the  PaCO2. It compares these 
two parameters to corresponding ideal and predicted 
values as a stand-in for Vd/Vt. This index has been vali-
dated in controlled modes of MV. The ventilatory ratio 
depends on  CO2 production, and any increase in  CO2 
production can modify its value. A value approximat-
ing 1 would represent normal ventilating lungs [21]. In 
non-COVID ARDS patients, a high ventilatory ratio is 
associated with mortality [22, 23].
We have previously reported that the ventilatory ratio 
is elevated in COVID ARDS patients [24]. In a series 
of 267 COVID-ARDS patients, Schenck et al. [25] also 
found higher values in those patients that remained 
intubated at day 3 and 7. They also found significantly 
higher values in the 47 deceased patients (median ven-
tilatory ratio of 2.26 [1.53–2.50]). In a sample of only 8 
patients, Liu et al. [26] found the ventilatory ratio was 
lower in those patients that received lower tidal vol-
umes. None of these three studies performed multivari-
able analyses of mortality. Finally, the Provent COVID 
data [27] including 927 consecutive mechanically ven-
tilated patients shows that the quantification of the 
impairment of ventilation using dead space estimates 
(dead space fraction, ventilatory ratio, and end-tidal to 
arterial  PCO2 ratio), neither at baseline nor in the fol-
lowing days, is not significantly associated with 28 day 
mortality. The exclusion or not of patients receiving 
ECMO was not specifically reported [27]. In addition, 
other important differences between this study and 
ours are that severity of ARDS was higher in our study ( 
51% vs 10%) and that we have included delta differences 
between day 3 and day 1 which not seems to be the case 
in the Morales Quintero study [27].
Our multivariable regression models showed that an 
increase in ventilatory ratio at ICU admission was associ-
ated with in-hospital mortality, with each unit increasing 
risk-of-death by 7% ([1–14], p = 0.015). Delta of ventila-
tory ratio at day 3 was also associated with mortality, with 
each unit-increase rising risk-of-death by 5% ([1–10], 
p = 0.030). In comparison with previous studies in non-
COVID ARDS patients, Sinha et  al. found that ventila-
tory ratio was independently associated with in-hospital 
mortality after adjusting for  PaO2/FiO2 ratio and driving 
pressure (OR 1.51 [CI 1.09–2.12), p = 0.015) [22]. It can 
be argued that our findings on ventilatory ratio could be 
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expected after Sinha´s et al. results on non-COVID ARDS 
[22]. However, we think that they were necessary after 
all the controversies about ARDS COVID phenotypes. 
Another important difference compared to Sinha et  al. 
[22] is that we demonstrated not only the prognostic value 
of ventilatory ratio at day 1 but the prognostic value at day 
3 as well, which gives a lot consistency for our data.
Interpretation of the ventilatory ratio is complex, but 
it can be considered as a surrogate marker of physiologic 
dead space [22]. Increased dead space in COVID 19 may 
be due to a combination of hypoperfused alveoli due to 
microthrombosis of capillary alveoli plus interstitial 
edema that impairs pulmonary circulation [28]. In rela-
tion to the first mechanism (microthrombosis), neither 
we nor Barbeta et  al. [24] found a correlation between 
the blood levels of D-dimer and the ventilatory ratio. In 
addition, we did not find significant correlations of VR 
with platelets, or compliance. We found a weak correla-
tion with  PaO2/FiO2. Sinha et  al. also found a negative 
correlation between  PaO2/FiO2 and ventilatory ratio, 
suggesting that ventilation–perfusion mismatch conduct 
to hypercarbia and hypoxemia [22]. Nevertheless, in our 
study ventilatory ratio exceeds  PaO2/FiO2 in predicting 
in-hospital mortality. In fact, for its association to the 
extent of poorly aerated lung tissue [29], the physiologic 
dead space has been suggested as a stronger predictor 
than oxygenation of the non-COVID ARDS outcomes 
[30]. Unlike typical ARDS, the profound hypoxemia 
observed in COVID-19 might be found in patients with 
relatively preserved lung volumes and respiratory com-
pliances [1], thus probably not reflecting the burden of 
parenchymal disease [31, 32].
Moreover, patients with higher dead space usually need 
higher minute ventilation to avoid hypercarbia, lead-
ing to an increase in lung injury due to higher dynamic 
mechanical power [33]. Indeed, the potential role of lung 
distension and ventilator-induced lung injury cannot be 
negligibly as the weak correlation between driving pres-
sure and ventilatory ratio at day 3 might show. It is pos-
sible that an increasing ventilatory ratio is a consequence 
of the progression of disease, but on the other hand it 
could also be a parameter that we could measure to mon-
itor the evolution of the patient when applying specific 
treatments and ventilatory strategies.
There are several limitations of this study. First, our meas-
urements on day 1 and 3 are only snapshots of the dynamic 
nature of COVID 19 respiratory failure (we chose the worst 
value). Second, we did not measure volumetric capnogra-
phy, and consequently, we were unable to assess the effects 
of metabolic rate on gas exchange. Metabolic rate can vary 
during fever and neuromuscular blockade. Third, and due to 
the observational nature of the study, the ventilation proto-
cols were not standardized, but the majority of centers used 
protective ventilation strategies. Fourth, it has been shown 
that the ventilatory ratio is increased when HME filters 
are used in comparison with the use of heated humidifiers. 
HME filters were used in most of our patients. Finally, the 
lack of a control group of ARDS non-COVID-19 patients it 
is another potential limitation. However, to collect contem-
porary solid data of this population was totally impossible 
due to the very low number of non-COVID patients admit-
ted during the study period in the different ICU’s which 
could have made impossible a solid matching with COVID-
19 ARDS patients.
The strengths of this study are its multicenter nature, 
the inclusion of a reasonably large number of patients 
with very homogeneous characteristics, and the perfor-
mance of multivariable analysis on day 1 of MV and at 
day 3, allowing us to consider the magnitude of changes 
that took place between day 1 and 3.
Conclusions
In conclusion, in a population of COVID 19 ARDS 
patients intubated at day 1 of ICU admission that 
remained ventilated after 3  days we found factors inde-
pendently associated with in-hospital mortality both 
at day 1 and most importantly, changes that occurred 
between day 1 and day 3 that were predictors of out-
come. Higher levels of creatinine and ventilatory ratio at 
day 1 and higher increase in ventilatory ratio and creati-
nine levels and lower increase in platelets at day 3 were 
independently associated with in-hospital mortality. We 
found that age and chronic respiratory diseases were also 
independently associated with in-hospital mortality. The 
 PaO2/FiO2 ratio at ICU admission and its worsening or 
improvement at day 3 was not associated with progno-
sis. Further interventional and prospective studies are 
needed to determine treatments and strategies that could 
decrease the ventilatory ratio.
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